These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28282547)

  • 21. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996.
    Cotter DJ; Thamer M; Kimmel PL; Sadler JH
    Kidney Int; 1998 Dec; 54(6):2129-39. PubMed ID: 9853279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Italian study on the treatment of anaemia in chronic dialysis patients switched over to less frequent doses of darbepoetin from human recombinant erythropoietin (rHuEPO)].
    Del Vecchio L; Villa G; Carraro G; Morosetti M; Pedrini L; Adorati Menegato M; Amato M; Mauro MM; Borgatti P; Malberti F; Marai P; Locatelli F;
    G Ital Nefrol; 2004; 21(3):259-66. PubMed ID: 15285005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.
    Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
    Clin Exp Pharmacol Physiol; 2016 Mar; 43(3):343-54. PubMed ID: 26889660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pattern of blood levels of erythropoietin and proinflammatory cytokines in patients with anemia of chronic disorders secondary to infection].
    Poveda Gómez F; Camacho Siles J; Quevedo Morales E; Fernández Zamorano A; Codoceo Alquinta R; Arnalich Fernández F; Sempere Alcocer M
    An Med Interna; 2001 Jun; 18(6):298-304. PubMed ID: 11503575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia.
    Garrido P; Ribeiro S; Fernandes J; Vala H; Rocha-Pereira P; Bronze-da-Rocha E; Belo L; Costa E; Santos-Silva A; Reis F
    Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26712750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leptin and serum erythropoietin in hemodialyzed and peritoneally dialyzed uremic patients during rHuEPO therapy.
    Małyszko J; Zbroch E; Wołczyński S; Małyszko JS; Hryszko T; Myśliwiec M
    Am J Nephrol; 2000; 20(3):180-6. PubMed ID: 10878398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell function, T-cell phenotype and its role in responsiveness to recombinant human erythropoietin in hemodialysis patients.
    Abdalla M; Yassein S; Darwish KH
    Egypt J Immunol; 2010; 17(2):67-80. PubMed ID: 23082488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impacts of recombinant human erythropoietin treatment during predialysis periods on the progression of chronic kidney disease in a large-scale cohort study (Co-JET study).
    Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Watanabe Y; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
    Ther Apher Dial; 2014 Apr; 18(2):140-8. PubMed ID: 24720404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory factors for hypoalbuminemia in Japanese peritoneal dialysis patients.
    Shioya M; Yoshida T; Kasai K; Furuya R; Kato A; Mori N; Matsumoto Y; Kumagai H
    Nephrology (Carlton); 2013 Aug; 18(8):539-44. PubMed ID: 23718260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
    Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
    de Sousa FT; Prata MM; Barbas JV; dos Santos JP
    Acta Med Port; 1990; 3(6):347-52. PubMed ID: 2089856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients?
    Macdougall IC
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V73-78. PubMed ID: 15284364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Lui SF; Chung WW; Leung CB; Chan K; Lai KN
    Clin Nephrol; 1990 Jan; 33(1):47-51. PubMed ID: 2302870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients.
    Cheng IK; Lu HB; Wei DC; Cheng SW; Chan CY; Lee FC
    Am J Nephrol; 1993; 13(2):142-8. PubMed ID: 8342581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
    Henry DH; Abels RI
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: a long-term study.
    Cheng IK; Cy C; Chan MK; Yu L; Fang GX; Wei D
    Clin Nephrol; 1991 May; 35(5):207-12. PubMed ID: 1855328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ITDI is the preferred treatment for iron supplementation in rHuEpo-treated anemic PD patients.
    Ahsan N
    Adv Perit Dial; 1998; 14():228-31. PubMed ID: 10649730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term therapy with recombinant human erythropoietin decreases percentage of CD152(+) lymphocytes in primary glomerulonephritis haemodialysis patients.
    Trzonkowski P; Myśliwska J; Debska-Slizień A; Bryl E; Rachoń D; Myśliwski A; Rutkowski B
    Nephrol Dial Transplant; 2002 Jun; 17(6):1070-80. PubMed ID: 12032199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized prospective comparison between erythropoietin and androgens in CAPD patients.
    Navarro JF; Mora C; Macía M; García J
    Kidney Int; 2002 Apr; 61(4):1537-44. PubMed ID: 11918762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.